CQN-PHENOM
Fourth paragraph, first sentence of release dated October 6, 2021, should read: As the vice president and general manager for Phenom in Central Europe, Gerstner will be responsible for strengthening existing and new customer relationships in Central Europe, including Germany, Austria, Switzerland, France and BENELUX (instead of in Germany, Austria and Switzerland).
The updated release reads:
PHENOM HIRES SENIOR LEADERS TO OVERSEE RAPID GROWTH IN EUROPE
Thomas Gerstner and Andy Joeres bring decades of experience scaling SaaS enterprises in EMEA
Phenom , the global leader in Talent Experience Management (TXM), today announced the hiring of two executives to drive the company’s surging global growth. Thomas Gerstner will lead Phenom’s business in Central Europe, and Andy Joeres will oversee initiatives in the United Kingdom and Ireland, Northern Europe, Middle East and Africa. The positions were created to continue building momentum in EMEA, where there has been an exploding demand for talent experience, AI and automation from HR teams.
Following numerous acquisitions and the addition of many enterprise customers in EMEA, Phenom’s headcount in Europe has quickly exceeded 100 employees. With operations in the United Kingdom, Ireland, Germany, Netherlands, France, Italy, Spain, Sweden, and Switzerland, Phenom expects to continue aggressively recruiting into 2022 across customer success, sales, account management, marketing, engineering, product and more.
“The need for AI-powered talent experiences is universal, and the interest in Phenom’s platform originating from EMEA is increasing every day,” said Mahe Bayireddi, co-founder and CEO of Phenom. “We’re thrilled that Andy and Thomas are joining our team. They carry proven track records of success meeting ambitious business objectives in many different markets around the world, and we expect their leadership will inspire our talented overseas team to bring amazing talent experiences to global enterprises.”
As the vice president and general manager for Phenom in Central Europe, Gerstner will be responsible for strengthening existing and new customer relationships in Central Europe, including Germany, Austria, Switzerland, France and BENELUX. In his last role, he was the EMEA president of Pathlock — defining, implementing, and executing growth strategy across all channels. For 14 years, Gerstner also held various senior executive roles at SAP, including senior vice president for the SuccessFactors business in the Middle and Eastern European region and managing director in Asia.
“Phenom is already turning heads in Central Europe, and it’s incredible to now be part of this special journey,” said Gerstner. “Organisations that have invested in AI-powered talent experiences are miles ahead of their competitors. Already in Central Europe, Phenom’s sophisticated platform is making a huge difference, helping organizations transform the way they acquire, develop and retain talent.”
Joeres will serve as Phenom’s vice president of sales for EMEA, where he will focus on bringing new business to the company. Joeres has managed the launch of hyper-growth initiatives for companies like Celonis and Snow, where he spearheaded triple-digit, year-over-year growth and exponentially scaled personnel from small teams to large units with deep impact across the enterprise.
“My passion has always been designing go-to-market strategies and then executing them for companies that have a clear, profound vision,” said Joeres. “HR teams are realizing that intelligent experiences are the present and future of hiring and retaining the best talent — and the Phenom TXM platform is the solution. AI and automation are now requirements for scaling those experiences. I look forward to championing Phenom’s platform to help organisations reduce cost and time to hire, while increasing employee retention.”
About Phenom
Phenom is a global HR technology company with a purpose to help a billion people find the right job. With an expertise in building AI-powered, scalable solutions, Phenom Talent Experience Management (TXM) personalizes and automates the talent journey for candidates, recruiters, employees and management with its Career Site, Chatbot, CRM, CMS, SMS and Email Campaigns, University Recruiting, Internal Mobility, Career Pathing, Diversity & Inclusion, Talent Marketplace, Gigs, Referrals, Hiring Manager and Analytics. As a result, employers improve their talent acquisition and talent management efforts by helping candidates and employees find the right job, recruiters identify and engage the right talent, and management optimizes HR strategy, process and spend. Phenom was ranked among the fastest-growing technology companies in the 2020 Deloitte Technology Fast 500, and won a regional 2020 Timmy Award for launching and optimizing HelpOneBillion.com.
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com . Connect with Phenom on LinkedIn , Twitter , Facebook , YouTube and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005383/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom